Aspiriant Holdings S3’s VanEck Biotech ETF BBH Stock Holding History

Aspiriant Holdings S3’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	$3.2M	Sell	25,206 -115	-0.5%	-$14.1K	1.38%	32
2015 Q3	$2.9M	Sell	25,321 -370	-1%	-$49K	1.33%	34
2015 Q2	$3.46M	Sell	25,691 -674	-3%	-$89.6K	1.38%	31
2015 Q1	$3.42M	Sell	26,365 -390	-1%	-$49K	1.36%	31
2014 Q4	$3.09M	Sell	26,755 -950	-3%	-$107K	1.27%	34
2014 Q3	$2.93M	Sell	27,705 -12,765	-32%	-$1.29M	1.18%	36
2014 Q2	$3.86M	Buy	40,470 +790	+2%	+$70.8K	1.54%	24
2014 Q1	$3.61M	Sell	39,680 -2,340	-6%	-$227K	1.52%	27
2013 Q4	$3.72M	Buy	42,020 +1,195	+3%	+$99.9K	1.46%	32
2013 Q3	$3.38M	Sell	40,825 -340	-0.8%	-$26.7K	1.43%	39
2013 Q2	$2.82M	Buy	+41,165	New	+$2.86M	1.27%	41

Other funds holding BBH

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BPC

Banque Pictet & Cie Geneva 73, Switzerland $14.2B AUM 20.68% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

VFAM

Valley Forge Asset Management King Of Prussia, Pennsylvania $645M AUM 5.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Aspiriant Holdings S3's BBH Position: Q4 2015 in Review

Aspiriant Holdings S3 reduced its VanEck Biotech ETF (BBH) stake by 0.45% in Q4 2015, selling an estimated $14.1K and leaving 25,206 shares worth $3.2M. The position accounts for 1.38% of the portfolio, ranked #32.

Aspiriant Holdings S3 first reported a position in BBH in Q2 2013 and has held it in 11 quarters since. The position peaked at $3.86M in Q2 2014. 90 funds tracked by Wall St. Rank hold BBH as of Q4 2015.

Aspiriant Holdings S3 held 25,206 shares of VanEck Biotech ETF worth $3.2M as of Q4 2015.
Aspiriant Holdings S3 sold 115 VanEck Biotech ETF shares in Q4 2015, an estimated $14.1K.
VanEck Biotech ETF made up 1.38% of Aspiriant Holdings S3's portfolio in Q4 2015, its #32 holding.
Aspiriant Holdings S3 first reported a position in VanEck Biotech ETF in Q2 2013 and has held it in 11 quarters since.
Aspiriant Holdings S3's VanEck Biotech ETF position peaked at $3.86M in Q2 2014.
90 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q4 2015.

Based on Aspiriant Holdings S3's 13F filing for Q4 2015, filed 13 Jan 2016.